National Lung Matrix Trial (NLM)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2014
  • Initiating Organization: Cancer Research UK
  • Initiator Type: Government
  • Disease focus:
  • Location: Europe
National Lung Matrix Trial


The National Lung Matrix Trial is the world’s largest precision medicine trial in non-small cell lung cancer and is pivotal in developing novel therapies for patients with this devastating disease. It is a clinician-led collaborative study among the University of Birmingham, Cancer Research UK, Astra Zeneca, and Pfizer. The trial is sponsored by the University of Birmingham and coordinated by the Cancer Research UK Clinical Trials Unit (CRCTU), with Gary Middleton leading as chief investigator.


The National Lung Matrix trial consists of a series of parallel, multi-center, single-arm Phase II trials, each arm testing an experimental targeted drug in a population stratified by multiple prespecified target biomarkers. There are currently 8 targeted drugs and 21 drug-biomarker combinations. The aim is to determine whether there is sufficient signal of activity in any drug-biomarker combination to warrant further investigation. The trial uses a Bayesian adaptive design that gives a more realistic approach to decision-making and flexibility to make conclusions without fixing the exact sample size.

Consortium History

January 2015: Trial announced and launch meeting held in Birmingham


Cancer Research UK, AstraZeneca, and Pfizer jointly fund the program, with support from the National Health Service. In total, this represents about £25 million worth of research.

Sponsors & Partners


Astra Zeneca

Cancer Research UK


University of Birmingham

Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.